Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-based versus mTOR-inhibitor-free immunosuppression after liver transplantation for hepatocellular carcinoma
ChiCTR-TRC-11001513Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of adverse events and Rate of hepatocellular carcinoma recurrence. Started Jan 2009; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001513.